Phillip J Mease (Philip Mease, Phillip Mease, Philip J Mease)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 214

Top Venues

RMD open

The Journal of rheumatology

Annals of the rheumatic diseases

Rheumatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, Phillip J Mease, Fabian Proft
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD open 10 (1) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Phillip J Mease, Atul A Deodhar
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial. Arthritis care & research (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology (2024)
Gizem Ayan, Sibel Zehra Aydın, Laura C Coates, Lihi Eder, Dafna D Gladman, Philip S Helliwell, Gurjit S Kaeley, Arthur Kavanaugh, Phillip J Mease, Stephen R Pennington, Fabian Proft, Enrique Roberto Soriano, Oliver M FitzGerald
GRAPPA 2023: Major Projects, Key Advances, and Milestones. The Journal of rheumatology (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) 76 (9) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Phillip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B McInnes
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy (2024)
Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, Phillip J Mease, Fabian Proft
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD open 10 (1) (2024)
Phillip J Mease, George Reed, Alexis Ogdie, Dimitrios A Pappas, Joel M Kremer
Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large US Registry. Arthritis care & research (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology (2024)
Lihi Eder, Jordi Pardo Pardo, Phillip J Mease, Lianne S Gensler
Comment on: Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials. Rheumatology (Oxford, England) (2024)
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Phillip J Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy 11 (3) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, Phillip J Mease, Fabian Proft
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD open 10 (1) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Phillip J Mease, Eros Papademetriou, Ravi Potluri, Ekta Agarwal, Joseph Christopher Cappelleri, You-Li Ling
Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases. Advances in therapy (2024)
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Phillip J Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Phillip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD open 10 (1) (2024)
André Lucas Ribeiro, Shikha Singla, Vinod Chandran, Nicholas Chronis, Wilson Liao, Christine Lindsay, Enrique Roberto Soriano, Phillip J Mease, Fabian Proft
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatology advances in practice 8 (3) (2024)
Phillip J Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy 11 (2) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Phillip J Mease, George Reed, Alexis Ogdie, Dimitrios A Pappas, Joel M Kremer
Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry. Arthritis care & research (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Phillip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B McInnes
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
André Lucas Ribeiro, Shikha Singla, Vinod Chandran, Nicholas Chronis, Wilson Liao, Christine Lindsay, Enrique Roberto Soriano, Phillip J Mease, Fabian Proft
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatology advances in practice 8 (3) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Phillip J Mease, Joseph Frank Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewe, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C Coates
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatology and therapy (2024)
Phillip J Mease, George Reed, Alexis Ogdie, Dimitrios A Pappas, Joel M Kremer
Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry. Arthritis care & research 76 (9) (2024)
Oliver FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Arthur Kavanaugh, Phillip J Mease, Laure Gossec, Roberto Ranza, Shigeyoshi Tsuji, Kevin Douglas, Michael Lane, Ralph Lippe, Manish Mittal, Tianming Gao, Arathi Setty, Sandra Ciecinski, Daniel Aletaha, Peter Nash
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials. ACR open rheumatology (2024)
Phillip J Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy 11 (2) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Phillip J Mease, Andrew Blauvelt, Adam P Sima, Silky W Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark G Lebwohl
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatology and therapy (2024)
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Phillip J Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy 11 (3) (2024)
Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, Phillip J Mease, Fabian Proft
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD open 10 (1) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Phillip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD open 10 (1) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, Phillip J Mease, Fabian Proft
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD open 10 (1) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Phillip J Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy 11 (3) (2024)
Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Phillip J Mease, Atul A Deodhar
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis care & research 76 (8) (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Vinod Chandran, Dafna D Gladman, Phillip J Mease, Lihi Eder, Stephen R Pennington, Oliver M FitzGerald, Christopher T Ritchlin, Dan E Webster, Kurt de Vlam, Wilson Liao
GRAPPA 2023 Collaborative Research Network Meeting. The Journal of rheumatology (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Phillip J Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Laure Gossec, Laura C Coates, Dafna D Gladman, Jacob A Aelion, Jitendra Vasandani, Andreas Pinter, Joseph F Merola, Arthur Kavanaugh, Jyotsna Reddy, Rebecca Wang, Michele Brunori, Yuri Klyachkin, Cynthia Deignan, Phillip J Mease
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Annals of the rheumatic diseases (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Phillip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 63 (7) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Phillip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD open 10 (1) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Dafna D Gladman, Philip S Helliwell, Phillip J Mease
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary. The Journal of rheumatology (2024)
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Phillip J Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy 11 (3) (2024)
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Phillip J Mease, Philip S Helliwell
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD open 10 (1) (2024)
Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Phillip J Mease, Atul A Deodhar
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis care & research (2024)
Phillip J Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy 11 (2) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Iain B McInnes, Phillip J Mease, Yoshiya Tanaka, Laure Gossec, M Elaine Husni, Lars Erik Kristensen, Richard B Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B Gottlieb
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies. ACR open rheumatology (2024)
Kevin L Winthrop, John Dudley Isaacs, Phillip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Thomas Wj Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the rheumatic diseases (2023)
Phillip J Mease, Peter Nash, Suzanne M Dolwick Grieb, Vinod Chandran
Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis. The Journal of rheumatology (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Laura C Coates, Phillip J Mease, Dafna D Gladman, Sandra Navarra, Weibin Bao, Corine Gaillez
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD open 9 (2) (2023)
Dennis McGonagle, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, Phillip J Mease
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR open rheumatology (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Laura C Coates, Phillip J Mease, Dafna D Gladman, Sandra Navarra, Weibin Bao, Corine Gaillez
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD open 9 (2) (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Kevin L Winthrop, John Dudley Isaacs, Phillip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Thomas Wj Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the rheumatic diseases (2023)
Phillip J Mease, Philip S Helliwell, Diamant Thaҫi, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael S Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph Frank Merola
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy (2023)
Phillip J Mease, Alice B Gottlieb, Philip S Helliwell, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Kishimoto Mitsumasa, Proton Rahman
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical rheumatology (2023)
Beverly Cheok Kuan Ng, Deepak R Jadon, Frank Behrens, Maarten P T de Wit, Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Denis O'Sullivan, Stephen R Pennington, Larissa Valor-Méndez, Vinod Chandran, Kurt de Vlam
Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting. The Journal of rheumatology (2023)

Phillip J Mease.css-eqlu8i{font-size:small;padding-left:4px;} (Philip Mease, Phillip Mease, Philip J Mease)

Publication Activity (10 Years)

Top Topics

Top Venues

Phillip J Mease (Philip Mease, Phillip Mease, Philip J Mease)